CardioSignal’s innovative approach to heart disease detection, utilizing smartphone technology, is poised to revolutionize healthcare globally.
CardioSignal’s groundbreaking technology leverages the sensors in smartphones to detect major heart diseases without the need for specialized medical equipment. By analyzing gyroscope and accelerometer motion data, the application can accurately measure specific rotational movements of the heart, providing users with valuable insights into their cardiovascular health.
The simplicity of the process is remarkable – users need only lie down and place their smartphone on their chest for one minute while the CardioSignal application performs the check. This ease of use eliminates barriers to access, making heart health monitoring more accessible to individuals worldwide.
Impact and Potential
With heart diseases remaining a leading cause of death globally, CardioSignal’s technology has the potential to make a significant impact on public health. David J. Kim, managing director of DigiTx Partners, emphasized the technology’s potential to detect various heart conditions, thereby lowering the barrier to adoption by making it readily available to anyone with a smartphone.
The Series A funding round, which raised 10 million US dollars, will enable CardioSignal to further validate its technology clinically and expand its commercial reach. This expansion will provide primary care doctors and their patients with a comprehensive solution for earlier detection and remote monitoring of heart conditions.
Empowering Primary Care with Advanced Detection Tools
Dr. Juuso Blomster, founder and CEO of CardioSignal, highlighted the current limitations in primary care for detecting heart diseases, particularly for patients already experiencing symptoms. CardioSignal’s technology fills this gap by offering primary care physicians advanced detection tools that are easy to use and accessible to all patients with smartphones.
The company’s commitment to research and development is evident in its extensive portfolio of patents and clinical algorithms, backed by more than 20 peer-reviewed scientific publications. This scientific foundation ensures the reliability and accuracy of CardioSignal’s technology, instilling confidence in both healthcare professionals and users alike.
Global Reach and Continued Growth
Despite its headquarters in Turku, Finland, CardioSignal’s impact is already felt on a global scale, with its application available in 15 countries. The company’s subsidiary in Palo Alto, California, further facilitates its expansion into international markets and collaboration with leading institutions and investors.
The recent Series A funding round, led by DigiTx Partners and supported by Sandwater and existing investor Maki.vc, underscores the growing recognition and support for CardioSignal’s mission. With a total funding raised to date amounting to 23 million US dollars, CardioSignal is well-positioned for continued growth and innovation in the field of heart health technology.
CardioSignal’s pioneering use of smartphone technology represents a transformative approach to heart disease detection, offering accessible, reliable, and advanced solutions for individuals and healthcare providers worldwide.
To know more visit – https://cardiosignal.com/
To read more startup stories visit –https://finlandbusinesspress.fi/